Current reports
Filing Types
VistaGen Therapeutics, Inc.
Companies

131 filings

Newest first
Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
VTGN VistaGen Therapeutics, Inc.
30 Jun 20
VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update
8-K
VTGN VistaGen Therapeutics, Inc.
26 Jun 20
Collaboration intended to support Phase 3 development and commercialization of PH94B in key Asian markets
8-K
VTGN VistaGen Therapeutics, Inc.
1 Jun 20
VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions
8-K
VTGN VistaGen Therapeutics, Inc.
18 May 20
The Proposed Phase 2A Open-label Study will be Conducted in New York City
8-K
VTGN VistaGen Therapeutics, Inc.
28 Apr 20
VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19
8-K
VTGN VistaGen Therapeutics, Inc.
27 Apr 20
Entry into a Material Definitive Agreement
8-K
VTGN VistaGen Therapeutics, Inc.
3 Apr 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8-K
VTGN VistaGen Therapeutics, Inc.
26 Mar 20
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
8-K
VTGN VistaGen Therapeutics, Inc.
21 Feb 20
VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder
8-K
VTGN VistaGen Therapeutics, Inc.
13 Feb 20
VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
8-K
VTGN VistaGen Therapeutics, Inc.
31 Jan 20
Company also Receives a Notice of Allowance from the USPTO for a New AV-101 U.S. Patent for Treatment of Dyskinesia Induced by Levodopa Therapy
8-K
VTGN VistaGen Therapeutics, Inc.
27 Jan 20
Entry into a Material Definitive Agreement
8-K
VTGN VistaGen Therapeutics, Inc.
27 Dec 19
Regulation FD Disclosure
8-K
VTGN VistaGen Therapeutics, Inc.
12 Dec 19
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
8-K
VTGN VistaGen Therapeutics, Inc.
14 Nov 19
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
8-K
VTGN VistaGen Therapeutics, Inc.
8 Nov 19
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
8-K
VTGN VistaGen Therapeutics, Inc.
30 Oct 19
Other Events
8-K
VTGN VistaGen Therapeutics, Inc.
9 Oct 19
Regulation FD Disclosure
8-K
VTGN VistaGen Therapeutics, Inc.
25 Sep 19
Other Events
8-K
VTGN VistaGen Therapeutics, Inc.
6 Sep 19
Amendments to Articles of Incorporation or Bylaws